ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DYN Dyne Therapeutics Inc

34.69
-0.73 (-2.06%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dyne Therapeutics Inc NASDAQ:DYN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.73 -2.06% 34.69 34.69 35.25 35.78 34.04 35.43 4,744,343 22:57:16

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

30/05/2024 12:30pm

GlobeNewswire Inc.


Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart


From Jun 2024 to Jun 2024

Click Here for more Dyne Therapeutics Charts.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203

1 Year Dyne Therapeutics Chart

1 Year Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart